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Cirrhotic Cardiomyopathy
Enrico M. Zardi, MD,* Antonio Abbate, MD, PHD,† Domenico Maria Zardi, MD,‡
Aldo Dobrina, MD,§ Domenico Margiotta, MD,* Benjamin W. Van Tassel, PHARMD,†
Antonella Afeltra, MD,* Arun J. Sanyal, MD
Rome and Trieste, Italy; and Richmond, Virginia
Cirrhotic cardiomyopathy is a clinical syndrome in patients with liver cirrhosis characterized by an abnormal and
blunted response to physiologic, pathologic, or pharmacologic stress but normal to increased cardiac output and con-
tractility at rest. As many as 50% of cirrhotic patients undergoing liver transplantation show signs of cardiac dysfunc-
tion, and 7% to 21% of deaths after orthotopic liver transplantation result from overt heart failure. In this review, we
critically evaluate the existing literature on the pathophysiology and clinical implications of cirrhotic cardiomyopathy.
(J Am Coll Cardiol 2010;56:539–49) © 2010 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.12.075P
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bore than 50 years ago, it was noted that persons with
lcohol-related cirrhosis had increased cardiac output, and it
as attributed to either impaired thiamine utilization or the
resence of an endogenous vasodilator (1). Cardiac hyper-
rophy and cardiomyocyte edema in the absence of coronary
rtery disease, hypertension, or valvular disease were next
escribed in an autopsy series of subjects with cirrhosis (2).
ubsequent studies described an impaired hemodynamic
esponse to physiologic (exercise) and pharmacologic stress
espite a high resting cardiac output (3).
These findings were then confirmed in animal models of
lcoholic cirrhosis and found to be related to decreased
yocardial contractile function (4), and finally were corrob-
rated by additional human studies (5,6).
This syndrome is formally described as cirrhotic cardio-
yopathy, which is defined as chronic cardiac dysfunction
n patients with cirrhosis characterized by blunted contrac-
ile responsiveness to stress and/or altered diastolic relax-
tion with electrophysiological abnormalities, in the absence
f known cardiac disease and irrespective of the causes of
irrhosis, although some etiologies (e.g., iron overload and
lcohol consumption) further impact on myocardial struc-
ure and function.
This syndrome is considered to be related to both portal
ypertension and cirrhosis (7) and is characterized by
ntrinsic alterations in myocardial function.
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ascular Dysfunction
ystemic vascular resistance and cardiac dysfunction.
dvanced liver disease is associated with marked changes in
ystemic vascular resistance. In a model of pre-sinusoidal portal
ypertension in rats, splanchnic arterial vasodilation is observed
nd is accompanied by a decreased contractile response to
itroprusside or isoproterenol and impaired myocyte calcium
ignaling, showing that portal vascular change and portosys-
emic shunting cause cirrhotic cardiomyopathy independent, at
east in part, of parenchymal liver disease (8–10).
Sinusoidal portal hypertension, in contrast, is characterized
y increased hepatic sinusoidal resistance to blood flow. This
as both a fixed component due to fibrotic disruption of the
rchitecture and a dynamic component due to changes in the
ontractility of the hepatic stellate cells and myofibroblasts in
he hepatic sinusoids (11). These cells are sensitive to a number
f vasoactive mediators, for example, endothelins, prostaglan-
ins, and nitric oxide (NO). Sinusoidal NO production is
mpaired in subjects with cirrhosis because of increased caveo-
in expression (12,13). In contrast, there is an increased NO
rive in the peripheral arterial circulation, especially in the
planchnic bed, that causes vasodilation. Other mediators
mplicated in the splanchnic arterial vasodilation seen in
irrhosis include carbon monoxide (CO) and endogenous
annabinoids (14,15).
The resting hyperdynamic state in cirrhosis reflects,
herefore, an initial appropriate response to splanchnic
rterial vasodilation (15,16).
olume expansion. In patients with cirrhosis, blood
olume expansion occurs before ascites formation. With
rogressive hepatic decompensation, there is a redistri-
ution of this expanded blood volume with a relative
ecrease in the central circulation and increment in the
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despite an absolute increase in
blood volume, there is marked ac-
tivation of sodium (Na) and wa-
ter retentive pathways, which be-
come more pronounced as
cirrhosis worsens. This is driven
mainly by the state of progressive
arterial vasodilation and imbalance
between the blood volume on one
hand and the space it has to oc-
cupy on the other (Fig. 1).
Arterial compliance. Peripheral
arterial vasodilation and arterial
compliance are closely associated.
With progression of cirrhosis,
there is a decrease in the thickness
of the vessel walls as well as a
decrease in total vascular wall area
14). The vascular tone is also decreased, possibly because of
educed smooth muscle mass secondary to NO overproduction
r altered endothelial function as well as alterations in extra-
ellular matrix turnover (18). Increased expression of large
onductance, calcium-activated potassium (K) channel 
ubunits have also been implicated as a cause of vascular
emodeling and altered arterial compliance in cirrhosis (14).
Abbreviations
and Acronyms
cAMP  cyclic adenosine
monophosphate
cGMP  cyclic guanosine
monophosphate
iNOS  inducible nitric
oxide synthase
MAPK  mitogen-activated
protein kinase
NOS  nitric oxide
synthase
RyR2  ryanodine receptor
SNS  sympathetic
nervous system
TIPS  transjugular
intrahepatic portosystemic
shunt
Figure 1 Clinical Basis of Blunted Cardiac Response
In the setting of liver cirrhosis and portal hypertension, a wide spectrum of factors
logical abnormalities, diastolic dysfunction, and systolic dysfunction. Cardiomyocyt
ment are also implied in this process. With advanced liver disease, these factorspidemiology, Natural History,
nd Clinical Presentation
imited information is available about the epidemiology of
irrhotic cardiomyopathy in humans, as its diagnosis is
ifficult because of near normal cardiac function at rest. The
ajority of patients are diagnosed during phases of clinical
ecompensation of cirrhosis in which they present with
eatures of diastolic heart failure and/or high-output heart
ailure (5) (Table 1). The actual prevalence of this condition
s unknown. Therefore, not much is known also regarding
he natural history of the disease. The condition is undoubt-
dly well tolerated and asymptomatic for months to years,
nd in many cases the symptoms are not easily distinguished
rom those of the underlying disease. Similarly, the natural
istory in terms of response to treatment and prognosis is
nclear. Increased arterial compliance in cirrhosis leads to a
unctional hypovolemia (decreased pre-load) despite a vol-
me overload in absolute terms. The blunted cardiac re-
ponse of cirrhotic cardiomyopathy fails to overcome the
ecrease in effective circulating volume because of arterial
asodilation. Conversely, splanchnic arterial vasodilation
nloads the ventricle and may mask the presence of ven-
ricular insufficiency. Autonomic dysfunction and impaired
olume and baroreceptor reflexes may also contribute to the
lunted cardiac response. In a calcium tetrachloride model
as volume expansion and hyperdynamic circulation, contribute to electrophysio-
ma membrane abnormalities, cytokines, growth factors, and autonomic impair-
ad to cardiac failure. ATPase  adenosine triphosphatase; CO  cardiac output., such
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August 10, 2010:539–49 Cirrhotic Cardiomyopathyf cirrhosis, rapid correction of the functional hypovolemia
ith saline infusion caused a rapid drop in cardiac output
19). The human corollary of this experiment is the devel-
pment of heart failure and pulmonary hypertension after
apid increase in venous return after transjugular intrahepatic
ortosystemic shunt (TIPS) or liver transplantation (20).
Therefore, the presence of a reduced cardiac workload,
avored by splanchnic arterial vasodilation, which is in turn
aused by progressive hepatic decompensation, may mask
ardiac insufficiency. In fact, echocardiography often shows
hat patients with decompensated cirrhosis have normal
ardiac function; however, physiologic or pharmacological
tress, bacterial infections (e.g., spontaneous bacterial peri-
onitis), TIPS, or liver transplantation may unmask alter-
tions in myocardial function, thus revealing the presence of
irrhotic cardiomyopathy.
A broad spectrum of cardiac alterations characterizes the
linical presentation of cirrhotic cardiomyopathy (Fig. 2),
hat may be distinctively viewed as a high-output heart
ailure (Table 1) (21,22), although the chronological se-
uence in which abnormalities develop is not fully defined.
lectrophysiologic changes. Multiple electrical abnormal-
ties have been recognized in cirrhosis (QT-interval abnor-
alities, electrical and mechanical dyssynchrony, chrono-
ropic incompetence) whose development seems linked to
utonomic dysfunction (defects in the sympathetic nervous
ystem [SNS] and vagal impairment), severe portal hyper-
ension and liver dysfunction, cytokines, and endotoxins
23,24). These electric abnormalities are independent of the
linical Presentation of Cirrhotic CardiomyopathyTable 1 Clinical Presentation of Cirrhotic Cardiomyopathy
Diagnostic Methods Clinical S
Echocardiography
Dynamic magnetic resonance cardiac imaging
Radionuclide angiography multigated acquisition
Myocardial perfusion imaging with gating
Systolic time intervals (measured through
simultaneous recording of electrocardiogram,
phonocardiogram, and external carotid
arterial pulse tracing using multichannel
photographic recording system)
High-output heart failure un
Blunted cardiac response to
Diastolic dysfunction
Systolic dysfunction
Electrocardiography after necessary adjustment Prolonged QT time
Disturbances of excitation-c
Cardiac serum markers Presence of BNP concentra
Elevated pro-BNP concentra
Presence of troponin I conc
Vasodilator serum markers Serum levels of
Nitric oxide
Carbon monoxide
Endocannabinoids
Endothelin-3
PGI2
Adrenomedullin
Vasoconstrictor serum markers Serum levels of
Angiotensin
Endothelin-1
Vasopressin
NP  brain natriuretic peptide; LV  left ventricular; PGI2  prostacyclin.ause of cirrhosis. sT-INTERVAL PROLONGATION. Prolongation of the QT-
nterval is well known to increase the risk for ventricular
achyarrhythmias. Prolongation of the QT-interval (0.44 s)
s seen even with mild increments in portal pressure in
ubjects with cirrhosis (24) and in noncirrhotic patients with
ortal hypertension, whereas a further increase has been
escribed after TIPS insertion (21). Both delayed repolar-
zation of cardiomyocytes due to K channel abnormalities
nd sympathoadrenergic hyperactivity may contribute to
T-interval prolongation (23,25). The QT-interval disper-
ion has been associated with the severity of liver dysfunc-
ion (26). It also varies from daytime to nighttime, probably
eflecting diurnal variations in autonomic tone, circulatory
tatus, and respiratory and oxygen demand (26). The QT-
nterval corrects itself in only 50% of subjects after a liver
ransplant (23). A recalculation of QT intervals based on
eart rate and other liver-related parameters are now
ndicated to better dissect out the contribution of changes
n QT-interval to heart-related morbidity and mortality
n subjects with cirrhosis (27). According to some au-
hors, QT-interval prolongation might be an important
ign helpful to identify patients with cirrhosis at risk of
irrhotic cardiomyopathy (22).
LECTRICAL AND MECHANICAL DYSSYNCHRONY. Some
ases of sudden death from ventricular arrhythmias have been
eported in patients treated with vasopressin during variceal
leeding or when undergoing plasma exchange (28). In animal
odels, chronic ligation of the portal vein has been shown to
educe excitation-contraction coupling due to decreased den-
Diagnostic Criteria
sting conditions E/A ratio 1
Prolonged deceleration time (200 ms)
Prolonged isovolumetric relaxation time (80 ms)
Enlarged left atrium
Decreased pattern of contractility
Decreased wall motion
Increased wall thickness
Resting ejection fraction 55%
Ratio of pre-ejection period to LV ejection time is prolonged
tion coupling
0.44 s (rate-corrected)
on
Elevation correlates with cirrhosis, cardiac dysfunction, and
prolonged QT time
Elevation correlates with low ventricular stroke volume and
increased LV mass index
They are imbalanced in cirrhosis during hepatic
decompensation phase
They are imbalanced in cirrhosis during hepatic
decompensation phaseigns
der re
stress
ontrac
tion
tion
entratiity of the L-type calcium channel (10). Disturbances of
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Cirrhotic Cardiomyopathy August 10, 2010:539–49xcitation-contraction coupling have also been observed in
irrhotic patients with QT-interval prolongation, which may
e attributable to defective K channel function in ventricular
ardiomyocytes (29). The role of changes in intracellular
alcium (Ca2) and potassium (K) in the extracellular milieu
articularly after variceal hemorrhage and blood transfusion in
ediating electromechanical dyssyncrony remains to be fully
lucidated.
notropic and chronotropic incompetence. In a study of
irrhotic subjects without ascites, Na loading caused an
ncreased end-systolic volume even though the resting
emodynamics were relatively normal (6). After the devel-
pment of ascites, there was more overt evidence of con-
ractile dysfunction despite a decrease in both afterload
arterial vasodilation) and pre-load (venous return) (6). Both
ypertensive and normotensive subjects with compensated
irrhosis show a reduction in cardiac index and an increase
n systemic vascular resistance (30). These data have been
onsidered to represent underlying “pump dysfunction.”
he hearts of cirrhotic subjects show a blunted ability to
ncrease heart rate or left ventricular ejection fraction after
ppropriate stimulation with exercise, drug infusion, or
ostural challenge (31). These data are corroborated by
ther studies where an infusion of atrial natriuretic factor in
irrhotic subjects led to a decrease in stroke volume and
ardiac index despite an increase in heart rate (32).
Another cause of decreased cardiac response to exercise is
decrease in maximal heart rate. This is closely correlated
Figure 2 Clinical View on Relationship Between Clinical and In
Progressive deterioration of cardiac function in cirrhosis may be recognized by me
and echocardiographic abnormalities whose severity is predictive of contemporaryith the decreased cardiac output response. It is hypothe- (ized that impaired cardiovascular reflex regulation and
iminished sensitivity to SNS activation might contribute to
he observed chronotropic incompetence (33).
iastolic dysfunction. Diastolic dysfunction in cirrhosis
as first reported in 1997 (5). Although some diastolic
lterations may precede the systolic disturbances, both
orms of dysfunction may develop simultaneously in cir-
hotic patients. Eccentric left ventricular hypertrophy devel-
ps in bile duct ligated rats in conjunction with develop-
ent of a hyperdynamic syndrome; this is associated with
ncreased collagen content and increased ventricular stiffness
34) that induces a prolonged, slowed, or incomplete ven-
ricular relaxation. Diastolic dysfunction has also been
eported in noncirrhotic portal hypertension and in patients
ith ascites but without cardiac hypertrophy (35). Whereas
he increased venous return seen after TIPS is expected to
ncrease myocardial stretch and thus stroke volume, in a
tudy of alcohol-related cirrhosis, diastolic dysfunction was
nmasked by TIPS causing, in some cases, pulmonary
dema and heart failure (36). Diastolic dysfunction may also
esult from impaired myocardial relaxation. This is related
o the on-off rate of Ca2 from troponin and the rate at
hich Ca2 returns to the sarcoplasmic reticulum through
he Ca2–adenosine triphosphatase pump or Na/Ca2
xchanger. Interestingly, after paracentesis, patients with
irrhosis show an improvement of diastolic dysfunction, as
emonstrated by an increased ratio of early to late diastolic
lling (E/A ratio) and a decreased deceleration time (5)
ental Abnormalities and Cardiac Function
clinical, electrocardiographic (ECG),
sness of heart failure. CO  cardiac output.strum
ans of
seriouTable 1). In fact, parvalbumin improves diastolic dysfunc-
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August 10, 2010:539–49 Cirrhotic Cardiomyopathyion (37), suggesting that improved hemodynamic outcomes
fter albumin infusion in subjects with spontaneous bacterial
eritonitis may be partly due to a direct effect on the
yocardium. Clinically, subjects with a thicker ventricle and
ore severe diastolic dysfunction are more likely to have
eart failure after liver transplantation (22). The diastolic
ysfunction tends to return to normal 6 to 12 months after
liver transplant (38).
ystolic dysfunction. A number of animal and human studies
n cirrhosis have shown evidence that systolic function is
pparently normal or even increased at rest, yet becomes
mpaired after stress, exercise, or other forms of stimuli (4–6).
entricular function is impaired after pharmacologically in-
uced stress in patients with alcoholic cirrhosis (39). Several
tudies of cirrhotic patients showed a decreased cardiac re-
ponse with inotropic and chronotropic incompetence after
harmacologic or exercise-induced increase in afterload or
eart rate (22,31); in fact, contrary to the expected increase, left
entricular ejection fraction did not change.
Although the systolic dysfunction has been attributed
o the effects of alcohol on the myocardium in subjects
ith cirrhosis, it is also present in those with nonalco-
olic causes of cirrhosis (4), as has been evaluated by
ssessing ventricular contractile performance, at rest and
fter exercise, through the measurement of systolic time
ntervals (derived from the simultaneous tracings of
lectrocardiogram, carotid artery pulse, and phonocardio-
ram) (28) (Table 1). In these cirrhotic patients, total
lectromechanical systole was prolonged because of the
engthening of systolic time intervals influenced by elec-
romechanical coupling such as electromechanical delay
nd pre-ejection period, probably related to a reduced
esponse to the adrenergic drive (28).
Systolic dysfunction, however, worsens with increasing
iver failure. The presence of ascites does not affect the
ystolic dysfunction, and it is also unaffected by thera-
eutic paracentesis (5). It has been suggested that systolic
ysfunction may be influenced by pre-load, afterload, and
iastolic dysfunction, but reduced myocardial reserve and
mpaired oxygen extraction (probably due to the local
mbalanced NO production and function) emerge to be
he main factors (22).
Recently, endocannabinoids have been implicated as
otential cause of impaired myocardial contractility in a
arbon tetrachloride mouse model of cirrhosis (40).
athogenic Mechanisms
he series of cardiac alterations that characterize the
linical presentation of cirrhotic cardiomyopathy depend
n the several pathogenic mechanisms listed in the
ollowing text.
mpaired Receptor Function
everal potential molecular causes for impaired myocardial
unction in cirrhosis have been identified. These include
hanges in cardiomyocyte plasma membranes, -adrenoceptor (ensity and function, altered K channels, altered L-type
a2 channels, and altered Na/Ca2 exchanger (41).
ole of cardiomyocyte plasma membrane changes. In a
tudy of a bile duct-ligated cirrhotic rat model, cardiomyocytes
ad significant increases in plasma membrane cholesterol
ontent and cholesterol-to-phospholipid molar ratio resulting
n a decrease in plasma membrane fluidity compared with
ham-operated controls (42). In this model, cyclic adenosine
onophosphate (cAMP) production in response to adrenergic
timulation was decreased; this was restored with correction of
he membrane fluidity (Fig. 3). In a separate study of choles-
atic cirrhotic rats, bile acid itself decreased plasma membrane
uidity in cardiac ventricles (43).
ole of ventricular -adrenoceptors. The observed de-
rease in chronotropic and inotropic responses to -
drenergic stimulation (9) in cirrhosis may be due to either
ecreased -adrenergic receptor density or function. Indeed, a
ecrease in -adrenoceptor density has been observed concom-
tantly with the changes in membrane fluidity noted in the
receding text (42). The decrease in membrane fluidity from
ncreased cholesterol further impairs signaling from the re-
aining receptors after ligand binding by inhibition of
-adrenergic receptor coupling with stimulatory G proteins
44). Given the key role of altered membrane fluidity in
-adrenergic receptor dysfunction and the presence of de-
reased membrane fluidity in many animal models of cirrhosis,
t appears that defective -adrenergic receptor function is
niversally present in cirrhotic cardiomyopathy.
ole of ventricular muscarinic receptors. Five muscarinic
cetylcholine receptor subtypes are known: M1, M3, and
5 muscarinic receptors couple to stimulate phospholipase
, whereas M2 and M4 muscarinic receptors inhibit ad-
nylyl cyclase (44). However, only M2 and M3 receptors are
xpressed in heart tissue, and M1, M2, and M3 receptors
re detected in vascular endothelial cells (45). In particular,
uscarinic receptors reside in both the atria and ventricles
ut have a greater density in the former (46). They are more
revalent in the endocardium than in the epicardium.
uscarinic receptors exist on T tubules in cardiomyocytes,
oronary arteries (including small vessels), and endothelial
ell membranes of capillaries. Muscarinic receptors are
bundant on sinoatrial and atrioventricular nodal cells (47).
he antagonistic effects of muscarinic versus -adrenergic
timulation are well described in ventricular myocytes (48).
n a rat model of bile duct ligated cirrhosis, investigators
eported blunted muscarinic (M2) responsiveness and de-
ective signal transduction to cAMP (49).
However, as discussed previously, plasma membrane
lterations in cirrhosis models may impair all post-receptor
ardiomyocyte systems involving cAMP. The potential role
f altered M1 and M3 receptors in cirrhotic cardiomyopathy
emains to be described.
ole of ventricular K channels. Ventricular K chan-
els are activated by a fall in cytoplasmic adenosine
riphosphate concentration and function as a voltage-
ndependent “brake” to modulate myocyte depolarization
50). Activation of K channels is essential for both early
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Cirrhotic Cardiomyopathy August 10, 2010:539–49nd final repolarization. The K channel activators
calcitonin gene-related peptide, adenosine, and so forth)
romote hyperpolarization and relaxation whereas inhib-
tors (noradrenaline, 5-hydroxytryptamine, neuropeptide
, angiotensin II, endothelin-1, and so forth) cause
epolarization and contraction. A rat model of bile duct
igated cirrhosis found decreased current density for all 3
ypes of K channels in isolated ventricular myocytes
Ca2-independent transient outward K current, de-
ayed rectifying K current, and inward rectifying K
urrent) (25). As a consequence of the decreased K
urrent density, cirrhotic rats exhibited a longer duration
f baseline action potential as compared with ventricular
yocytes of sham-operated rats (25). These observations
ay contribute to the QT-interval prolongation previ-
usly described in cirrhotic patients.
A rapid change from a “short” to a “long” action potential
ommand waveform may cause an immediate decrease in
eak Ca2-dependent current and a marked slowing of its
ecline (51).
Therefore, a marked prolongation of the action potential
Figure 3 Molecular Basis of Blunted Cardiac Response
Gap-junction linked cardiomyocytes in which plasma membrane, myosin-actin cross
following cardiomyocyte abnormalities: 1) reduced cholesterol plasma membrane c
myocardial -adrenoceptor density and a dysfunction of adrenergic intracellular sig
3) alteration of muscarinic receptors (in particular, receptor M2 inhibits adenylyl cy
ing phospholipase C); and 4) the density of K channels is reduced, probably bec
gene-related peptide and adenosine, while noradrenaline, 5-hydroxytryptamine, neu
triphosphate; RyR2  ryanodine receptor Ca2 release channels.ight maintain the cardiomyocyte in a contracted state and dmpair relaxation (49). The inwardly rectifying background
 current is believed to be the main ionic current respon-
ible for setting the resting membrane potential in mam-
alian heart cells and also to influence the late phase of
epolarization (52); therefore, the inwardly rectifying back-
round K current may have some effect on cardiomyocyte
notropy depending on the overall status of regulation of
ntracellular Ca2 concentration, the key driver of the
yocardial contractility.
ole of extracellular and sarcoplasmic reticulum calcium
hannels. In cardiac myocytes, depolarization of the plas-
alemma opens L-type voltage-gated Ca2 channels that
ause activation of Ca2-stimulated Ca2 release from
he sarcoplasmic reticulum through ryanodine receptors
RyR2). Phosphorylation of RyR2 and decreased sarcoplas-
ic reticulum Ca2 can decrease the calcium available for
elease (53). The decline of Ca2 content and the conse-
uent myocardial relaxation occur through Ca2 reuptake
n the sarcoplasmic reticulum and expulsion of Ca2 from
he cytosol into the extracellular space by adenosine
riphosphate-driven calcium pumps and ion gradient-
e, and sarcoplasmic reticulum are clearly depicted. This picture elucidates the
t and alteration in cholesterol-to-phospholipid molar ratio; 2) downregulation of
by G protein, adenylyl cyclase, and cyclic adenosine monophosphate (cAMP);
and receptors M1 and M3 are linked to intracellular signaling pathways, includ-
f plasma membrane alterations. The receptor function is stimulated by calcitonin
tide Y, angiotensin II, and endothelin-1 show inhibitory action. ATP  adenosine-bridg
onten
naling
clase,
ause o
ropepependent Na/Ca2 exchangers. A decrease in initial
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August 10, 2010:539–49 Cirrhotic Cardiomyopathya2 entry as well as decreased Ca2-stimulated Ca2
elease have been noted in cardiac myocytes in a bile duct
igated model of cirrhosis (54) (Fig. 4). A decrease in density
f L-type channels and sarcolemmal calcium content has
een reported in other studies (16). Crosstalk between
arcolemmal L-type Ca2 channels and the sarcoplasmic
eticulum might be fundamentally important to ensure
dequate Ca2 kinetics for long-term excitation-contraction
oupling. Dysregulation of this process remains to be
escribed in detail.
ole of Na/Ca2 exchanger. The Na/Ca2 exchanger
lays an important role in maintaining a balance between
a2 influx and efflux. The Na/Ca2 exchanger is present
n all “external” membranes and exchanges 3 Na ions for 1
a2 ion (or 4 Na ions for 1 Ca2 ion) (55). The
a/Ca2 exchanger is, therefore, responsible for mainte-
ance of steady-state intracellular free Ca2 concentration,
lthough a small fraction of the Ca2 transport also depends
n a sarcolemmal Ca2 adenosine triphosphatase (56).
ince excess Ca2 influx contributes to cardiomyocyte
poptosis (57), abnormalities of the Na/Ca2 exchanger
Figure 4 Molecular Basis of Blunted Cardiac Response
Gap-junction linked cardiomyocytes in which plasma membrane, myosin-actin cross
following cardiomyocyte abnormalities: 1) L-type voltage-gated Ca2 channels cont
omyocyte -adrenoceptor is implied in inhibition of ryanodine receptor Ca2 releas
Ca2 concentration; 2) increased levels of carbon monoxide (CO) stimulate guanyl
phosphate (cGMP) that inhibits Ca2 release by sarcoplasmic reticulum; 3) canna
4) the increased circulating levels of tumor necrosis factor (TNF)-alpha and interleu
production; the NO induces apoptosis and inhibits RyR2, reducing Ca2 current.ight contribute the cirrhotic cardiomyopathy. This, how-
ver, remains to be elucidated.
olecular Mediators of Impaired
yocardial Function in Cirrhosis
ole of carbon monoxide. Carbon monoxide is an endo-
enously produced short-lived gas that favors splanchnic
rterial vasodilation. Cirrhosis may stimulate carbon monoxide
roduction through activation of the SNS, increased levels of
orepinephrine, or increased cytokinemia from the enhanced
ortal venous bacteremia and endotoxemia. Carbon monoxide
ay decrease ventricular contractility through increased cyclic
uanosine monophosphate (cGMP) and depressed calcium
nflux. In a rat model of bile duct-ligated cirrhosis, heme
xygenase messenger ribonucleic acid transcription, protein
xpression, and total heme oxygenase activity were significantly
pregulated in cirrhotic rat hearts but not in sham-operated
ontrol rat hearts (58).
ole of cannabinoids and their receptors. Endocannabi-
oids (e.g., anandamide) are lipids that are the endogenous
igands for cannabinoid receptors (59). Several mammalian
issues express 1 of 2 types of cannabinoid receptors: CB1,
e, and sarcoplasmic reticulum are clearly depicted. This picture elucidates the
to the Ca2 influx across the cell during depolarization; the dysfunction of cardi-
nels (RyR2) by a Ca2/calmodulin pathway leading to reduction of intracellular
ase in cirrhosis; this process leads to hyperexpression of cyclic guanosine mono-
receptor 1 (CB1) inhibition of -adrenoceptor function has been reported; and
)-1- stimulate inducible nitric oxide synthase (iNOS), leading to nitric oxide (NO)-bridg
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Cirrhotic Cardiomyopathy August 10, 2010:539–49xpressed in the brain and in several peripheral tissues
ncluding heart, endothelial cells (hepatic sinusoidal endo-
helial cells), smooth muscle cells, and perivascular nerves;
nd CB2, expressed in immune system cells. Cannabinoids
nduce splanchnic arterial vasodilation and have negative
notropic effects on cardiac contractility in cirrhosis. In a rat
odel of bile duct ligated cirrhosis, increased endocannabi-
oid signaling blunted the ventricular responsiveness to
-adrenergic stimuli by the CB1 receptor (60). A study in a
at model of carbon tetrachloride-induced cirrhosis showed
hat increased activity of the endocannabinoid/CB1 recep-
or system directly impaired cardiac contractility, whereas
ndocannabinoid/CB1 receptor blockade restored the nor-
al contractile function (40). The negative inotropic effect
f CB1 receptor might be the result of L-type calcium
hannel inhibition and cAMP reduction.
ole of NO. Nitric oxide is produced in cardiac microvas-
ular endothelial cells and cardiomyocytes from either con-
titutive or inducible nitric oxide synthase (NOS), which
atalyses the conversion of L-arginine to L-citrulline. Car-
iomyocytes principally express endothelial NOS, localized
ear invaginations of the plasmalemma termed caveolae,
nd neuronal NOS, localized on the sarcoplasmic reticulum
61). A third isoform, the inducible nitric oxide synthase
iNOS), may be expressed upon stimulation with inflam-
atory mediators. While NO synthesized by neuronal NOS
nd endothelial NOS has cardioprotective effects through
mprovement of perfusion and inhibition of apop-
osis, NO derived from iNOS has a cardiotoxic effect
hrough the suppression of muscle wall contractility and
nduction of apoptosis (62). Nitric oxide is released in a
ulsatile manner from the beating heart. Changes in ven-
ricular filling induce parallel increases or decreases in
ardiac NO synthesis, which, in turn, modulate the function
f ion channels and transporters involved in cardiac
xcitation-contraction coupling (63).
Preliminary observations indicated that NO overproduction-
nduced hyperdynamic circulation in cirrhosis and the con-
equent splanchnic arterial vasodilation masked the presence
f blunted cardiac function (19,20). However, experimental
tudies on cirrhotic animal models revealed the link between
OS, NO, and blunted cardiac response. Van Obbergh et al.
64) first elucidated the role of NOS in cirrhotic cardiomyo-
athy by demonstrating that treatment with the nonspecific
OS inhibitor, L-NMMA (N omega-monomethyl-L-
rginine), significantly increased ventricular contractility of
solated working hearts in cirrhotic rats. Thereafter, Liu et
l. (65) showed that high levels of NO were cardiodepres-
ant and that the heart and aorta of cirrhotic rats expressed
igh levels of iNOS messenger ribonucleic acid and endo-
helial NOS, respectively. Some lines of evidences support
he role of tumor necrosis factor- as a potent inducer of
NOS and, thereby, NO production (66). Conversely, NO
timulation of soluble guanylyl cyclase produces a 160- to
00-fold increase in cGMP as the second messenger effector
nd may cause bradycardia by blocking L-type channels and
mpairing the responsiveness of cardiac pacemaker cells to cdrenergic stimuli (54,66). Overproduction of NO and
euronal NOS overactivity may impair RyR2 function
hrough both classic cGMP-signaling and direct redox
odification of specific thiol residues in the RyR2 protein
63). In a rat model of bile duct-ligated cirrhosis, both
umor necrosis factor- and interleukin-1 exerted a neg-
tive inotropic effect in control papillary muscles through an
O-dependent mechanism, leading to the hypothesis that
O production played an important role in the pathogen-
sis of cirrhotic cardiomyopathy (65).
Other molecular pathways have also been investigated to
xplain the role of NO in cirrhotic cardiomyopathy. Per-
xynitrite is a reactive oxygen species, formed by the
eaction of NO with superoxide anion (O2), that may
nhibit cardiac function through nitration (or S-nitrosation)
f cardiac contractile proteins, such as actin (67). In a rat
odel of bile duct ligated cirrhosis, increased protein
itration in cardiac tissue was associated with reduced
hronotropic function (68). In a separate study of L-NAME
NG-L-nitro-arginine methyl ester) and N-acetylcysteine,
ecreased cardiac nitrotyrosine levels favored normalization
f cardiac function and further confirmed the inhibitory
ffect of nitration.
ole of Apoptosis in Impaired
yocardial Function in Cirrhosis
poptosis is a key cellular process that plays an important
ole of myocardial remodeling in heart failure (69).
itogen-activated protein kinases (MAPKs) are signaling
roteins that respond to a variety of stimuli. Of the MAPK
amily, p38-MAPK is particularly involved with growth,
roliferation, differentiation, and apoptosis (70). Several
irrhosis-inducing agents specifically activate p38-MAPK
n myofibroblasts (71). Gene transfer techniques show that
he p38-MAPK isoform, p38, contributes to cell death
fter ischemia and cardiomyocyte apoptosis (72). A selective
38/p38 isoform inhibitor, SB203580, protects cardiac
yocytes from ischemic damage, further confirming the
ro-apoptotic role for p38 (73). These effects are due to
nhibition of the  rather than the  isoform (74). Trans-
orming growth factor- is a potent pro-fibrogenic and
ro-apoptotic cytokine that causes its effects through smad
roteins and non-smad pathways, including the p38 MAPK
nd JUN NH2-terminal kinases. These, as well as trans-
orming growth factor- activity, are increased in cirrhosis.
rognosis
he patient with cirrhosis is a severely ill patient with an
verall unfavorable prognosis if liver transplant is not safely
erformed. While cirrhosis directly provides an increased
isk of cancer, bleeding, or infection, additional conditions
ay worsen the already poor prognosis of such patients. As
reviously stated, impaired cardiac function is often undi-
gnosed in cirrhosis yet leads to an increased risk of death
specially in the setting of acute decompensated cirrhosis,
onditions in which the inability of increasing cardiac
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August 10, 2010:539–49 Cirrhotic Cardiomyopathyutput likely contributes to unfavorable outcomes (28). The
mpaired cardiac output may indeed favor a decrease in renal
erfusion contributing to the pathogenesis of hepatorenal
yndrome (75). That is favored by the ensuing sympathetic
ctivation that tries to increase cardiac contractility but
timulates renal sodium and water retention also through
he activation of the renin-angiotensin-aldosterone system
76). Furthermore, when there is a rapid hemodynamic
hange (e.g., after TIPS or liver transplantation), the in-
reased filling pressure may favor the development of
ongestive heart failure. That is due both to the impaired
iastolic relaxation, already present but still unrevealed, that
auses elevated ventricular pressure thus favoring left atrium
ilation, and to the impaired heart rate and intrinsic
lterations of myocardium contractility. The ensuing
lunted cardiac function causes a decrease in the effective
irculatory volume, which induces a further increase in
odium retention. Thus, increasing sodium excretion
hrough diuretics, aldosterone-blockers especially, leads to
mproved function (77). The -adrenergic blockers are
ften used for patients with cirrhosis to reduce the portal
ypertension and prevent the gastroesophageal variceal
emorrhage; -blockers also ameliorate the cardiac contrac-
ion and function, both reducing QT-interval prolongation
ime and opposing the downregulation of -adrenoceptor
ensity (44). However, no longitudinal studies of diuretics
nd -blockers for cirrhotic cardiomyopathy are available.
onflicting results have also been obtained by the use of
ngiotensin-II receptor antagonists, which, despite a good
ncrease in sodium excretion without a change in renal and
ystemic hemodynamics (78), have not produced substantial
linical results after long-term treatment (79). On the
ontrary, according to some authors, angiotensin-converting
nzyme inhibitors could be of benefit (77), but further
tudies are necessary to prove their efficacy in cirrhotic
ardiomyopathy.
Because of the rapid shift of a large volume of blood from
he splanchnic area to the heart, TIPS, used to treat
efractory ascites and gastroesophageal variceal hemorrhage,
ften produces a worsening of the cardiac function in
atients with cirrhosis, especially in those with impaired
ardiac diastolic function (E/A ratio 1) (80).
Liver transplantation is also associated with cardiovascu-
ar complications (affecting almost 25% of patients), and
atients with an abnormal heart function during surgery are
t higher risk for post-operative pulmonary edema (81,82).
An improvement after liver transplant is expected and
alidates the concept that the cardiomyopathy is truly
irrhotic in origin (38). A study of 40 patients with cirrhosis
ndergoing liver transplantation reported the disappearance
f left ventricular hypertrophy and diastolic dysfunction as
ell as normalization of systolic response and exercise
apacity during stress (38).
In case of concomitant severe cardiomyopathy, heartransplantation has been considered (83).
2otential Therapeutic Approaches
o accepted pharmacologic treatment for cirrhotic cardio-
yopathy exists. Liver transplant is the cure for cirrhosis
nd is likely to cure the associated cardiomyopathy. While
aiting for targeted clinical trials, general knowledge and
onsiderations used for heart failure should be applied to
atients with cirrhosis (84). Agonists of farnesoid X recep-
or (a gene involved in intrahepatic generation of vasodilator
ydrogen sulfide) and NCX-1000 (a new compound that
eleases NO in the liver) are interesting new attempts aimed
t correcting the diminished production of endogenous
epatic vasodilators during cirrhosis (85,86), but their use-
ulness is not yet clear in cirrhotic cardiomyopathy.
At present, investigations on the gene expression pattern
f the cardiomyocyte adrenergic pathway in animal models
f cirrhosis are an attempt to better understand the causes of
he blunted cardiac response (87). New gene-targeting
harmacological strategies might be the future direction
oward which research will move.
onclusions
significant proportion of patients with cirrhosis affected
y ascites, volume overload, and signs of hyperdynamic
irculation have normal resting echocardiographic parame-
ers but abnormal cardiac responses during exertion, stress,
IPS, or liver transplantation, consistent with the existence
f a cirrhotic cardiomyopathy (81). Strict diagnostic criteria
or cirrhotic cardiomyopathy are lacking, and this syndrome
s often not recognized. Inability to increase cardiac output
hen necessary is likely a cofactor in cirrhosis complications
uch as hepatorenal syndrome or shock. No specific treat-
ent or management strategies has been tested for patients
ith cirrhotic cardiomyopathy. The presence of the cardio-
yopathy should be suspected in patients with worsening
emodynamics, and such patients may benefit from more
ggressive monitoring and treatment of the underlying
athology leading to decompensation, and close monitoring
uring procedures likely to cause decompensation (i.e.,
IPS, paracentesis, transplant). Clinical trials in this area
re eagerly awaited. In the meantime, management of
irrhotic cardiomyopathy, once identified, should follow the
ecommendations of the American College of Cardiology/
merican Heart Association guidelines for the treatment of
atients with heart failure (84). A better comprehension of
oth the complex hemodynamic changes during cirrhosis
nd the molecular pathways involved in the contractile
ysfunction of the cardiomyocyte may lead to improved care
f patients with cirrhotic cardiomyopathy.
eprint requests and correspondence: Dr. Enrico M. Zardi, Uni-
ersità “Campus Bio-Medico,” Via Àlvaro del Portillo, Rome
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